Spyre Therapeutics, Inc.
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases. Its pipeline centers on engineered antibodies and antibody combinations targeting α4β7, TL1A, and IL-23, with development activities organized through licensed programs and clinical trials.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSingle-agent antibody programs for inflammatory bowel disease, including SPY001, SPY002 and SPY003.
Fixed-dose or paired antibody combinations designed to improve efficacy, safety and convenience in IBD.
Antibody development for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.
Exclusive worldwide rights to develop, manufacture and commercialize selected antibody programs.
Customers
Spyre does not sell commercial products today; its direct counterparties are licensors, research partners, clinical trial participants, and future pharmaceutical buyers such as hospitals, specialists, and payers. The eventual end customers for approved therapies would be patients with IBD or rheumatic diseases, while commercialization would likely run through specialty prescribing channels and reimbursement systems.
Paragon and other IP holders that grant Spyre rights to antibody programs and related know-how.
Healthy volunteers and patients enrolled to generate safety, PK, ADA and efficacy data.
Gastroenterologists and IBD centers that would prescribe approved therapies for ulcerative colitis and Crohn's disease.
Rheumatologists treating RA, PsA and axSpA if the SPY072 program advances successfully.
Commercial and government payers that would determine access and reimbursement for biologic therapies.
Strategy
Spyre's strategy is to build a portfolio of long-acting antibodies with differentiated pharmacokinetics and to test them both as monotherapies and in combinations. It is also extending the anti-TL1A program into additional immune-mediated diseases, aiming to create a broader platform beyond IBD.
These are the core assets that could validate the company's IBD platform and future commercial value.
Combining complementary mechanisms may improve efficacy and convenience versus single antibodies.
A broader indication set can increase the addressable market for the anti-TL1A program.
Geography
Spyre is headquartered in Waltham, Massachusetts and operates as a U.S.-based development company. Its clinical programs are being studied in the United States and, for some trials, in certain other countries including parts of Europe and China through ethnobridging or multi-country enrollment.
Risks
Spyre is exposed to the binary risks of clinical-stage drug development, including trial failure, regulatory disagreement, and delays in patient enrollment or study design. It also depends on third-party licensors and manufacturers, and it will need substantial additional capital before any product can be commercialized.
- Clinical development failureImpact: CriticalLikelihood: High
The pipeline is still in Phase 1 and Phase 2, so efficacy and safety remain unproven.
Exposure - Capital requirements and dilutionImpact: HighLikelihood: High
The company funds R&D with external capital and has no commercial revenue base.
Exposure: Equity financings and ATM issuance
- Third-party relianceImpact: HighLikelihood: Medium
Licensors, CROs and manufacturers control key inputs to development and supply.
Exposure - Regulatory and trial-design riskImpact: HighLikelihood: Low
FDA or foreign regulators may disagree with platform-trial or basket-trial designs.
Exposure: SKYLINE and SKYWAY trials
- Intellectual property disputesImpact: MediumLikelihood: Medium
Engineered antibody programs operate in a crowded and litigious patent landscape.
Exposure: Global antibody IP rights
Accounting
Judgemental itemsClinical trial and vendor invoices often lag service delivery, so estimates affect expense timing.
Impact: Can shift quarterly operating loss and liabilities
The liability is measured using assumptions about probabilities, timing and discount rates.
Impact: Fair-value remeasurement can create non-cash volatility
Equity awards are a major compensation tool for a development-stage biotech.
Impact: Affects operating expense and dilution analysis
Any revenue depends on milestone, service and royalty terms under licensing agreements.
Impact: Revenue timing may be uneven and contract-specific
Similar listed companies
Publicly listed companies with a comparable business focus.
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Lyell Immunopharma, Inc.
LYEL · Pharmaceutical Preparations
Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer.
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Last updated: 24/09/2026